0525 GMT September 23, 2019
"While most therapies target the late stages of the eye disease in diabetes, these findings offer a much-needed approach to treat the disease much earlier, news-medical.net wrote.
"The re-purposing of a medication already FDA-approved for use in children and adolescents sets the stage for rapid translation of these animal model findings to human subjects," said Dr. Gubitosi-Klug, news-medical.net wrote.
"The daily dose equivalent used in the current study is similar to the once daily dose used in the treatment of asthma. Reassuringly, in our diabetes model as in asthma studies, this dose allows effective suppression of chronic inflammation, which can prevent pathology, but avoids complete inhibition of inflammation, which can compromise innate immunity."
"Moreover, montelukast was efficacious in both prevention and delayed intervention approaches, which implies relevance to patients with newly-diagnosed diabetes as well as individuals living with diabetes of longer duration," she said.
"Thus, there is promise that a safe treatment that effectively stabilizes airways in asthma may also preserve small blood vessels and nerve cells in diabetes."